European urology最新文献_第6页

Re: Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial 氨甲环酸在泌尿外科手术中的安全性和有效性：来自国际、随机、安慰剂对照的pase -3试验的结果。

IF 29.1 1区医学

European urology Pub Date : 2026-10-01 Epub Date: 2026-06-17 DOI: 10.1016/j.eururo.2026.05.010

Lin Chen, Wenlong Lu

引用次数: 0

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436 回复：Dries Develtere， Riccardo Bertolo。前列腺放疗后累积泌尿生殖系统毒性：高水平长期随机证据。J .临床肿瘤学。先在线，后印刷。http://dx.doi.org/10.1200/jco - 26 - 00436。

IF 29.1 1区医学

European urology Pub Date : 2026-10-01 Epub Date: 2026-07-03 DOI: 10.1016/j.eururo.2026.06.011

Astrid E. Persson, Gabriel Adrian

引用次数: 0

Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial [89Zr]吉伦妥昔单抗PET/CT预测肾脏恶性肿瘤的表现：对ZIRCON试验的再分析。

IF 29.1 1区医学

European urology Pub Date : 2026-10-01 Epub Date: 2026-04-22 DOI: 10.1016/j.eururo.2026.03.003

Aboubacar Kaba, Pratik Kanabur, Jeremie Calais, Andrew M. Scott, Jean-Christophe Bernhard, Peter C.R. Mulders, Bülent Önal, Tamer Aksoy, Michael Morris, Viraj Master, Brian Shuch

{"title":"Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial","authors":"Aboubacar Kaba, Pratik Kanabur, Jeremie Calais, Andrew M. Scott, Jean-Christophe Bernhard, Peter C.R. Mulders, Bülent Önal, Tamer Aksoy, Michael Morris, Viraj Master, Brian Shuch","doi":"10.1016/j.eururo.2026.03.003","DOIUrl":"10.1016/j.eururo.2026.03.003","url":null,"abstract":"<div><div>Carbonic anhydrase IX (CAIX) is a cell surface protein expressed in over 90% of clear cell renal cell carcinoma (ccRCC), driven by hypoxia or Von-Hippel Lindau (VHL) loss. The phase 3 ZIRCON trial evaluated [<sup>89</sup>Zr]girentuximab, a CAIX-targeted positron emission tomography (PET) radiotracer, and met its primary endpoint for the accurate detection of ccRCC in patients with renal masses. Many aggressive forms of non-ccRCC (nccRCC) can express CAIX, which is linked to a hypoxic state. A reanalysis of the trial was performed demonstrating the tracer also identified nccRCC, particularly in forms of papillary RCC (pRCC) with higher CAIX expression (H score) and PET avidity (SUVmax). The positive predictive value for any renal malignancy was 98%, with sensitivity/specificity of 82% and 87%, respectively. This suggests [<sup>89</sup>Zr]girentuximab has applications beyond the detection of ccRCC in primary renal masses and may have implications to management of nccRCC.</div></div><div><h3>Patient summary</h3><div>The ZIRCON phase 3 trial used an imaging agent ([<sup>89</sup>Zr]girentuximab) with a primary focus to detect the most common kidney cancer, clear cell renal cell carcinoma. Other forms of kidney cancer can express the marker that the imaging agent can identify. The additional analysis showed that when positive, 98% of cases were correctly identified as any form of cancer.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 330-332"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When the Platform Owns the Procedure: Intellectual Property Rights and Robotic Surgery 当平台拥有手术程序：知识产权和机器人手术。

IF 29.1 1区医学

European urology Pub Date : 2026-10-01 Epub Date: 2026-06-20 DOI: 10.1016/j.eururo.2026.05.036

Benjamin Davies, David Canes, Quoc-Dien Trinh, Jay Simhan, Alexander Kutikov

引用次数: 0

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial 前列腺立体定向放射治疗5年后患者报告的结果：来自PACE-B试验的结果。

IF 29.1 1区医学

European urology Pub Date : 2026-10-01 Epub Date: 2026-07-20 DOI: 10.1016/j.eururo.2026.05.034

Sian Cooper, Jaymini Patel, Caroline Moore, Peter Ostler, Hans van der Voet, Andrew Loblaw, William Chu, Daniel Ford, Shaun Tolan, Suneil Jain, Philip Camilleri, Kiran Kancherla, John Frew, Andrew Chan, Olivia Naismith, John Armstrong, John Staffurth, Alexander Martin, Ian Dayes, Paula Wells, Alison C. Tree

{"title":"Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial","authors":"Sian Cooper, Jaymini Patel, Caroline Moore, Peter Ostler, Hans van der Voet, Andrew Loblaw, William Chu, Daniel Ford, Shaun Tolan, Suneil Jain, Philip Camilleri, Kiran Kancherla, John Frew, Andrew Chan, Olivia Naismith, John Armstrong, John Staffurth, Alexander Martin, Ian Dayes, Paula Wells, Alison C. Tree","doi":"10.1016/j.eururo.2026.05.034","DOIUrl":"10.1016/j.eururo.2026.05.034","url":null,"abstract":"<div><div>Patient-reported outcome measures (PROMs) complement oncological endpoints by capturing what matters most to patients. The TrueNTH surgical collaboration presented 1-yr PROMs following robotic prostatectomy using accessible visual formats. We present 5-yr PROMs from the phase 3, international PACE-B trial, which randomised men with localised prostate cancer to stereotactic body radiotherapy (SBRT) or conventionally fractionated radiotherapy (CRT). PROMs are reported from baseline to 5 yr and presented using waffle charts to enable visual alignment with surgical outcomes. At 5 yr, urinary incontinence outcomes were favourable and comparable between SBRT and CRT. Leak-free rates were 64% (164/258) for SBRT and 69% (172/249) for CRT, pad-free rates were 91% (233/257) for SBRT and 90% (225/250) for CRT, and moderate or big urinary leakage problems were reported by only 6% (15/250) for SBRT and 4% (9/244) for CRT. Intercourse-adequate erections declined in both groups from baseline to 5 yr: from 35% (133/374) to 17% (43/250) for SBRT, and from 40% (157/391) to 20% (47/240) for CRT. Moderate or big sexual problems increased in both groups, from 24% (87/367) to 31% (74/242) for SBRT and from 22% (85/382) to 32% (77/238) for CRT. Bowel effects were low and comparable between groups, with moderate or big bowel problems reported by 2% (7/397) at baseline and 5% (12/265) for SBRT at 5 yr, and 2% (9/415) at baseline and 5% (13/253) for CRT at 5 yr. Stool incontinence as a moderate or big problem rose from <1% (1/374) to 2% (4/240) in the SBRT group and from <1% (1/395) to 3% (7/238) in the CRT group.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 321-327"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to Pierre-Etienne Gabriel and Evanguelos Xylinas’s Letter to the Editor re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol. 2026;89:93–5 回复Pierre-Etienne Gabriel和Evanguelos Xylinas给编辑的信。回复丁丁、雷茜、迪金等。基于适体的正电子发射断层成像允许特异性检测残余膀胱癌：首次在人类的研究。欧洲地理。2026；89:93-5

IF 23.4 1区医学

European urology Pub Date : 2026-10-01 DOI: 10.1016/j.eururo.2026.02.010

Ding Ding,Weijun Wei,Haige Chen,Weihong Tan

引用次数: 0

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer CISTO研究的12个月结果比较了根治性膀胱切除术与保留膀胱治疗复发的高级别非肌肉侵袭性膀胱癌

IF 23.4 1区医学

European urology Pub Date : 2026-10-01 DOI: 10.1016/j.eururo.2026.02.009

Laura E. Davis,Spyridon P. Basourakos,Adam C. Calaway

引用次数: 0

Re: Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008 主动监测与膀胱内卡介素-谷氨酰胺治疗第二次经尿道切除阴性的高级别T1膀胱癌：随机非劣效性3期JCOG1019试验Urol欧元。在出版社。http://dx.doi.org/10.1016/j.eururo.2026.01.008